Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus TC Regimen in Recurrent Metastatic Oral Squamous Cell Carcinoma
NCT04367909Phase 2Unknown
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in oral squamous cell carcinoma (OSCC). Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT04367909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04367909.